[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Josso et al., 1971 - Google Patents

Congenital abnormality of the prothrombin molecule (factor II) in four siblings: prothrombin Barcelona

Josso et al., 1971

View HTML
Document ID
70510250370643494
Author
Josso F
De Sanchez J
Lavergne J
Menache D
S0ULIER J
Publication year
Publication venue
Blood

External Links

Snippet

A family is described in which four siblings suffer from an unusual hemorrhagic syndrome. In the patient's plasma, the prothrombin level is only 5% of normal by standard clotting assay and 100% both by staphylocoagulase and immunochemical assays. Results of further …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Similar Documents

Publication Publication Date Title
Josso et al. Congenital abnormality of the prothrombin molecule (factor II) in four siblings: prothrombin Barcelona
Hougie et al. Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called “stable factor”(SPCA, proconvertin, factor VII) deficiency
De Vries et al. A factor in serum which accelerates the conversion of prothrombin to thrombin: I. Its determination and some physiologic and biochemical properties
Shapiro et al. Congenital dysprothrombinemia: an inherited structural disorder of human prothrombin
Langdell et al. Effect of antihemophilic factor on one-stage clotting tests: a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure
Miletich et al. Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a bleeding disorder
Björk et al. Acceleration of the Reaction between, Thrombin and Antithrombin III by Non‐stoichiometric Amounts of Heparin
Schiffman et al. Partial purification and characterization of contact activation cofactor.
Esmon et al. Protein C activation
Schiffman et al. The identification and synthesis of activated plasma thromboplastin component (PTC')
Biggs et al. Tissue extract and the contact reaction in blood coagulation
Girolami et al. Prothrombin Padua: A “new” congenital dysprothrombinemia
Lorand et al. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII)
Goldsmith et al. Studies on a family with combined functional deficiencies of vitamin K-dependent coagulation factors.
Saito et al. Partial purification of plasma thromboplastin antecedent (factor XI) and its activation by trypsin
Soff et al. Familial multiple coagulation factor deficiencies
Johnson et al. Characterization of a variant prothrombin in a patient congenitally deficient in factors II, VII, IX and X
Otis et al. An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations
Thompson et al. Removal of heparin and protamine from plasma
EP0044343B1 (en) Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions
Kahn et al. Prothrombin Brussels, a new congenital defective protein
Soulier et al. Further studies on thrombin-coagulase
Kessler et al. Stimulation of fibrinogen synthesis: a possible functional role of fibrinogen degradation products
Josso et al. A new variant of human prothrombin: prothrombin Metz, demonstration in a family showing double heterozygosity for congenital hypoprothrombinemia and dysprothrombinemia
Johnston et al. Development of increased factor VII activity during the spontaneous coagulation of blood